|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM124450148 |
003 |
DE-627 |
005 |
20250203221014.0 |
007 |
tu |
008 |
231222s2003 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed25n0415.xml
|
035 |
|
|
|a (DE-627)NLM124450148
|
035 |
|
|
|a (NLM)12672405
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Yang, Tian-Yu
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Prolongation of allogeneic skin graft survival by injection of anti-Ly49A monoclonal antibody YE1/48
|
264 |
|
1 |
|c 2003
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 01.05.2003
|
500 |
|
|
|a Date Revised 07.11.2019
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Ly49A receptors expressed on NK, NKT, and T cells play inhibitory roles in regulating the immune responses in vivo and in vitro. Whether or not injection of anti-Ly49A monoclonal antibody (mAb) YE1/48 can block allograft rejection has not been evaluated. Balb/c mouse recipients received intraperitoneal injections of YE1/48 mAb (0.5 mg) or control mAb or phosphate-buffered saline on days -1 and 10. On day 0, fully MHC-mismatched allogeneic C57BL/6 (B6) skin grafts were implanted. The skin graft survival and anti-donor humoral responses were observed. Whereas allogeneic B6 skin grafts survived 14 days in isotopy control antibody-treated or nontreated Balb/c mice, injection of YE1/48 mAb significantly prolonged B6 skin graft survival to 19 days (P < 0.0005). Injection of YE1/48 mAb into presensitized Balb/c recipients did not significantly delay B6 skin graft rejection. On the other hand, after depleting recipient NK, NKT, and some cytotoxic T cells by injection of anti-asialo GM1, YE1/48 failed to prolong B6 skin graft survival in Balb/c recipients. The present studies indicate that injection of YE1/48 mAb significantly delays allogeneic skin graft rejection in nonsensitized recipients but not in sensitized recipients. The presence of NK, NKT cells, and some cytotoxic T cells may be essential for YE1/48-mediated immunosuppression in vivo
|
650 |
|
4 |
|a Journal Article
|
650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
650 |
|
7 |
|a Antigens, Ly
|2 NLM
|
650 |
|
7 |
|a H-2 Antigens
|2 NLM
|
650 |
|
7 |
|a Histocompatibility Antigen H-2D
|2 NLM
|
650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
650 |
|
7 |
|a Isoantibodies
|2 NLM
|
650 |
|
7 |
|a Klra1 protein, mouse
|2 NLM
|
650 |
|
7 |
|a Lectins, C-Type
|2 NLM
|
650 |
|
7 |
|a Ligands
|2 NLM
|
650 |
|
7 |
|a NK Cell Lectin-Like Receptor Subfamily A
|2 NLM
|
650 |
|
7 |
|a Receptors, NK Cell Lectin-Like
|2 NLM
|
700 |
1 |
|
|a Sun, Yimin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Langnas, Alan N
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhao, Yong
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 106(2003), 2 vom: 29. Feb., Seite 148-54
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
773 |
1 |
8 |
|g volume:106
|g year:2003
|g number:2
|g day:29
|g month:02
|g pages:148-54
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 106
|j 2003
|e 2
|b 29
|c 02
|h 148-54
|